<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03122444</url>
  </required_header>
  <id_info>
    <org_study_id>CTMS 17-0037</org_study_id>
    <nct_id>NCT03122444</nct_id>
  </id_info>
  <brief_title>Imipramine on ER+ve and Triple Negative Breast Cancer</brief_title>
  <official_title>A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Previously Untreated Breast Cancer (CTMS# 17-0037)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology&#xD;
      specimen or repeat core needle biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly&#xD;
      diagnosed triple negative breast cancer comparing changes in biomarkers from a diagnostic&#xD;
      core needle biopsy to surgical pathology specimen or repeat core needle biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in the proliferation rate of triple negative breast cancer</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Imipramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imipramine will initially be 50mg and this will be increased by 50mg every other day as tolerated to 200 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine</intervention_name>
    <description>Imipramine will be given daily for 21-30 days.</description>
    <arm_group_label>Imipramine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants may be female or male who are 18 years old or older.&#xD;
&#xD;
          -  Ability to consent to treatment - patients or their legally authorized representative&#xD;
             must be informed of the investigational nature of this study and must sign and give&#xD;
             written informed consent in accordance with institutional and federal guidelines.&#xD;
&#xD;
          -  Previously untreated breast cancer determined by a core needle biopsy showing invasive&#xD;
             ductal carcinoma or invasive lobular carcinoma.&#xD;
&#xD;
          -  A prior, unrelated, breast cancer is allowed.&#xD;
&#xD;
          -  All breast cancers with possibility for surgical excision will be included.&#xD;
&#xD;
          -  Patient must be able to take oral medications. Patients may not have any impairment of&#xD;
             gastrointestinal function or gastrointestinal disease that may significantly alter the&#xD;
             absorption of the study drug.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum or urine beta human&#xD;
             chorionic gonadotropin (Î²-hCG) pregnancy test result within 14 days prior to the first&#xD;
             dose of imipramine.&#xD;
&#xD;
          -  Patients must be eligible for surgical resection of their breast cancer or repeat&#xD;
             biopsy after completing treatment.&#xD;
&#xD;
          -  Patients must have a complete history and physical examination within 30 days prior to&#xD;
             registration.&#xD;
&#xD;
          -  Patients must have a performance status of ECOG 0, 1, 2.&#xD;
&#xD;
          -  Tissue block of initial biopsy specimen is available.&#xD;
&#xD;
          -  Patient may not be concurrently enrolled in another investigational drug treatment&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known diagnosis of major depressive disorder, bipolar depression or psychosis&#xD;
&#xD;
          -  ECOG 3 or 4&#xD;
&#xD;
          -  Age &gt;= 70 years&#xD;
&#xD;
          -  Renal impairment defined as EGFR &lt;30&#xD;
&#xD;
          -  Hepatic impairment as judged by clinical investigator or bilirubin &gt;2&#xD;
&#xD;
          -  As judged by the investigator, severe uncontrolled concurrent medical conditions,&#xD;
             psychiatric illness or social condition that would limit compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  History of cardiac disease (arrhythmia, conduction abnormality, congenital prolonged&#xD;
             QT syndrome, or prolonged QTc rhythm noted during initial EKG &gt;480 ms)&#xD;
&#xD;
          -  Current use of SSRI, SNRI, MAO inhibitor, tramadol or trazadone; or use of these&#xD;
             agents within 14 days&#xD;
&#xD;
          -  Inflammatory breast cancer&#xD;
&#xD;
          -  Suicidal ideation or history of suicide attempt&#xD;
&#xD;
          -  Myocardial infarction within 3 months of study initiation.&#xD;
&#xD;
          -  Patients with Angle-Closure Glaucoma&#xD;
&#xD;
          -  Pregnant or breast-feeding women. As there have been no well-controlled studies&#xD;
             conducted with pregnant women to determine the effect of imipramine on the fetus.&#xD;
             However, there have been clinical reports of congenital malformations associated with&#xD;
             the use of the drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>71 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virginia G Kaklamani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Epp Goodwin</last_name>
    <phone>210-450-5798</phone>
    <email>ctrcreferral@uthscsa.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mays Cancer Center, UT Health San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Epp Goodwin</last_name>
      <phone>210-450-1000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2017</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Virginia G. Kaklamani</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

